


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A sulfonamide compound according to formula I



with its geometrical isomers, in an optically active form as enantiomers, diastereomers, as well as in the form of racemates, as well as pharmaceutically acceptable salts thereof, wherein

$\text{Ar}^1$  and  $\text{Ar}^2$  are independently from each other substituted or unsubstituted aryl or heteroaryl groups with the proviso that  $\text{Ar}^1\text{Ar}^2$  is not 1,3-phenylene or 1,4-phenylene,

$\text{X}$  is O or S;

$\text{R}^1$  is hydrogen or a C<sub>1</sub>-C<sub>6</sub>-alkyl group, or  $\text{R}^1$  forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with  $\text{Ar}^1$ ;

$n$  is an integer from 0 to 5;

$\text{Y}$  within formula I is a substituted or unsubstituted piperidino moiety, whereby one nitrogen atom within said

Appln. No. 10/070,954  
Amd. dated June 18, 2007  
Reply to Office Action of January 18, 2007  
Advisory Actions of May 2 and May 30, 2007


piperidino moiety forms a bond with the sulfonyl group of formula I thus providing a sulfonamide,

with the proviso that if Ar<sup>1</sup> is 4-chlorophenyl, then X is O, R<sup>1</sup> is H, Ar<sup>2</sup> is thienyl, and Y is not para-substituted by 2-hydroxyethyl,

with the further proviso that if Ar<sup>1</sup> is phenyl, then X is O, R<sup>1</sup> is H, Ar<sup>2</sup> is thienyl, and Y is not substituted in its β position by a benzo [5,6] cyclohepta [1,2b] pyridine or a benzo [5,6] cyclohept [3,4]ene [1,2b] pyridine;—unit

with the final proviso that if X is oxygen, then Y shall not be substituted by a group (C=O)N(R, R') at the α-position of the sulfonamide nitrogen.

2. (Currently Amended) A composition for treatment of disorders associated with the abnormal expression or activity of JNK comprising a sulfonamide compound according to formula I



with its geometrical isomers, in an optically active form as enantiomers, dia-stereomers, as well as in the form of racemates, as well as pharmaceutically acceptable salts thereof, wherein

Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2 and May 30, 2007

Ar<sup>1</sup> and Ar<sup>2</sup> are independently from each other substituted or unsubstituted aryl or heteroaryl groups with the proviso that neither A<sup>1</sup>-Ar<sup>1</sup> nor A<sup>2</sup>-Ar<sup>2</sup> is 1,3-phenylene or 1,4-phenylene and Ar<sup>1</sup> is not quinazoline that is substituted by nitro, hydroxyl, or 3,4-dichlorophenyl amino,

X is O or S;

R<sup>1</sup> is hydrogen or a C<sub>1</sub>-C<sub>6</sub>-alkyl group, or R<sup>1</sup> forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Ar<sup>1</sup>;


n is an integer from 0 to 5;

Y within formula I is a piperidino group whereby one nitrogen atom within said piperidino group forms a bond with the sulfonyl group of formula I thus providing a sulfonamide;

with the proviso that if Y is substituted at the β-position of the piperidino- nitrogen by a benzo[5, 6]cyclohepta[1, 2b]pyridine, or a benzo[5, 6]cyclohept [3, 4]ene [1, 2b]pyridine, while Ar<sup>2</sup> is thienyl, X is oxygen, R<sup>1</sup> is hydrogen and n is 1, Ar<sup>1</sup> shall not be a phenyl group;

and a pharmaceutically acceptable carrier with the final proviso that if X is oxygen, Y shall not be substituted by a group (C=O)N(R,R') at the α-position of the sulfonamide nitrogen.

3. (Currently Amended) A sulfonamide compound according to claim 1 or a composition according to claim 2, wherein Y is a piperidino group of the formula



whereby,  $L^1$  and  $L^2$  are independently selected from each other from the group consisting of H, substituted or unsubstituted  $C_1-C_6$ -alkyl, substituted or unsubstituted  $C_2-C_6$ -alkenyl, substituted or unsubstituted  $C_2-C_6$ -alkynyl, substituted or unsubstituted cyclic  $C_4-C_8$ -alkyl optionally containing 1-3 heteroatoms and optionally fused with aryl or heteroaryl; or  $L^1$  and  $L^2$  are independently selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aryl- $C_1-C_6$ -alkyl, heteroaryl- $C_1-C_6$ -alkyl,  $-C(O)-OR^3$ ,  $-C(O)-R^3$ ,  $-C(O)-NR^{3'}R^3$ ,  $-NR^{3'}R^3$ ,  $-NR^{3'}C(O)R^3$ ,  $\underline{-NR^{3'}C(O)NR^{3'}R^3}$ ,  $-NR^{3'}C(O)NR^{3'}R^3$ ,  $-(SO)R^3$ ,  $-(SO_2)R^3$ ,  $-NHSO_2R^3$ , and  $-SO_2NR^{3'}R^3$ ,

with  $R^3$  and  $R^{3'}$  being substituents independently selected from the group consisting of H, substituted or unsubstituted  $C_1-C_6$ -alkyl, substituted or unsubstituted  $C_2-C_6$ -alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl- $C_1-C_6$ -alkyl,

Appln. No. 10/070,954  
Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007  
Advisory Actions of May 2 and May 30, 2007

C<sub>6</sub>-alkyl and substituted or unsubstituted heteroaryl-C<sub>1</sub>-C<sub>6</sub>-alkyl;

said aryl or heteroaryl groups being optionally substituted C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, amino, acylamino, aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfonyl, sulfoxy, and C<sub>1</sub>-C<sub>6</sub>-thioalkoxy, and

R<sup>6</sup> is selected from the group consisting of hydrogen, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkoxy, OH, halogen, nitro, cyano, sulfonyl and oxo (=O), and

n' is an integer from 0 to 4.

Claim 4. (Cancelled)

5. (Previously Presented) A sulfonamide compound according to claim 1, wherein Ar<sup>1</sup> and Ar<sup>2</sup> are independently selected from the group consisting of phenyl, thienyl, furyl, pyridyl, and optionally substituted by C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, amino, acylamino, aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfonyl and C<sub>1</sub>-C<sub>6</sub>-thioalkoxy.

Reply to Office Action of January 18, 2007


Advisory Actions of May 2 and May 30, 2007

6. (Previously Presented) A sulfonamide compound according to claim 5, wherein Ar<sup>1</sup> is an unsubstituted or substituted phenyl.

7. (Previously Presented) A sulfonamide compound according to claim 5, wherein Ar<sup>2</sup> is an unsubstituted or substituted thienyl or furanyl group.

8. (Previously Presented) A sulfonamide compound according to claim 1, wherein Ar<sup>1</sup> is selected from the group consisting of a 4-chlorophenyl, nitrophenyl, hydroxyphenyl, alkoxy phenyl, pyridyl, 3,4,-dihydroxyphenyl, thioxo-dihydropyridine or its tautomer and pyrazole and X is O, R<sup>1</sup> is hydrogen, n is 1, Ar<sup>2</sup> is thienyl or furanyl.

9. (Currently Amended) A sulfonamide compound according to claim 8, wherein Y is



(R<sup>6</sup>)<sub>n'</sub> is selected from the group consisting of hydrogen, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub> alkoxy, OH, halogen, nitro, cyano, sulfonyl, and oxo; n' is an integer of from 0 to 4; and

wherein L<sup>1</sup> and L<sup>2</sup> are independently selected from each other from the group consisting of H, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>- alkyl, substituted or unsubstituted C<sub>2</sub>-C<sub>6</sub> alkenyl; or L<sup>1</sup> and L<sup>2</sup> are independently selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aryl-C<sub>1</sub>-C<sub>4</sub> alkyl, heteroaryl-C<sub>1</sub>-C<sub>4</sub> alkyl, -C(O)-OR<sup>3</sup>, -C(O)-R<sup>3</sup>, -C(O)-NR<sup>3'</sup>R<sup>3</sup>, -NR<sup>3'</sup>R<sup>3</sup>; ~~-NR<sup>3'</sup>C(O)R<sup>3</sup>~~, ~~-NR<sup>3'</sup>-C(O)NR<sup>3'</sup>R<sup>3</sup>-NR<sup>3'</sup>-C(O)NR<sup>3'</sup>R<sup>3</sup>~~, -(SO)R<sup>3</sup>, -(SO<sub>2</sub>)R<sup>3</sup>, -NHSO<sub>2</sub>R<sup>3</sup>, and -SO<sub>2</sub>NR<sup>3'</sup>R<sup>3</sup>;


with R<sup>3</sup> and R<sup>3'</sup> being substituents independently selected from the group consisting of H, substituted or unsubstituted C<sub>1</sub>-C<sub>4</sub> alkyl, substituted or unsubstituted C<sub>2</sub>-C<sub>6</sub> alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl; substituted or unsubstituted aryl-C<sub>1</sub>-C<sub>4</sub>-alkyl, substituted or unsubstituted heteroaryl-C<sub>1</sub>-C<sub>6</sub>-alkyl;

said aryl or heteroaryl groups being optionally substituted C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, amino, acylamino, aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfonyl, sulfoxy, C<sub>1</sub>-C<sub>6</sub>-thioalkoxy or said heteroaryl goups being a triazole ring fused with an unsubstituted or substituted aryl ring.

Appln. No. 10/070,954  
Amd. dated June 18, 2007  
Reply to Office Action of January 18, 2007  
Advisory Actions of May 2 and May 30, 2007

10. (Currently Amended) A sulfonamide compound according to claim 9, wherein R<sup>6</sup> is H, L<sup>2</sup> is H, L<sup>1</sup> is a 5-membered cyclic group containing 3 heteroatoms, or L<sup>1</sup> is -C(O)-R<sup>3</sup>, or -NHR<sup>3</sup>;

wherein Y is



n' is an integer of from 0 to 4;  
with R<sup>3</sup> being a substituent selected from the group comprising or consisting of C<sub>1</sub>-C<sub>4</sub>-alkyl, aryl, heteroaryl, aryl-C<sub>1</sub>-C<sub>4</sub>-alkyl and heteroaryl-C<sub>1</sub>-C<sub>6</sub>-alkyl;  
said aryl or heteroaryl groups being optionally substituted by halogen, hydroxy, nitro, or sulfonyl.

11. (Currently Amended) A sulfonamide compound according to claim 1, selected from the group consisting of:  
4-chloro-N-{5-[4-(3-trifluoromethanesulfonyl-phenylamino)-piperidine-1-sulfonyl]-thiophen-2-ylmethyl}-benzamide;

4-chloro-N-[ (5-{[4-(4-fluorobenzoyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

~~4-chloro-N-[ (5-{[4-(3-piperidin-1-ylpropyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;~~

Appln. No. 10/070,954

Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2 and May 30, 2007

4-chloro-N-((5-[(4-hydroxy-4-phenylpiperidin-1-yl)sulfonyl]thien-2-yl)methyl)benzamide;

N-((5-[(4-benzoylpiperidin-1-yl)sulfonyl]thien-2-yl)methyl)-4-chlorobenzamide;

4-chloro-N-[(5-{[4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-((5-[(4-benzylpiperidin-1-yl)sulfonyl]thien-2-yl)methyl)-4-chlorobenzamide;

4-chloro-N-[(5-{[4-(2,4-difluorobenzoyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

tert-butyl 1-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-ylcarbamate;

4-chloro-N-[(5-(piperidin-1-ylsulfonyl)thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-({3-hydroxy-4-[3-(trifluoromethyl)phenyl]piperidin-1-yl}sulfonyl)thien-2-yl)methyl]benzamide;

N-[(5-{[4-(benzyloxy)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

N-(4-chlorophenyl)-2-(5-{[4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)acetamide;

Appln. No. 10/070,954  
Amd. dated June 18, 2007  
Reply to Office Action of January 18, 2007

Advisory Actions of May 2 and May 30, 2007

4-chloro-N-({5-[ (4-hydroxypiperidin-1-yl)sulfonyl]thien-2-yl}methyl)benzamide;  
N-({5-[ (4-benzyl-4-hydroxypiperidin-1-yl)sulfonyl]thien-2-yl}methyl)-4-chlorobenzamide;  
N-{[5-({4-[ (2-tert-butyl-1H-indol-5-yl)amino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}-4-chlorobenzamide;  
4-chloro-N-{ [5-({4-[ (phenylacetyl)amino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;  
N-[(5- {[4-(2H-1,2,3-benzotriazol-2-yl)piperidin-1-yl}sulfonyl)thien-2-yl]methyl)-4-chlorobenzamide;  
4-chloro-N-[(5- {[4-(4-chlorobenzoyl)piperidin-1-yl}sulfonyl)thien-2-yl]methyl]benzamide;  
4-chloro-N-({5-[ (4-phenoxy)piperidin-1-yl)sulfonyl]thien-2-yl}methyl)benzamide;  
N-{[5-({4-[benzyl(methyl)amino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}-4-chlorobenzamide;  
4-chloro-N-{[5-({4-[3-(2,4-dichlorophenyl)-1H-pyrazol-5-yl)piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;  
4-chloro-N-[(5- {[4-(5-thien-2-yl-1H-pyrazol-3-yl)piperidin-1-yl}sulfonyl)thien-2-yl]methyl]benzamide;

Appn. No. 10/070,954  
Amd. dated June 18, 2007  
Reply to Office Action of January 18, 2007  
Advisory Actions of May 2 and May 30, 2007

4-chloro-N-[ (5-{ [4-(2,3,4,5,6-pentamethylbenzoyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[ 5-{ {4-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]piperidin-1-yl}sulfonyl}thien-2-yl]methyl]benzamide;

N-({5-[ (4-anilinopiperidin-1-yl)sulfonyl]thien-2-yl)methyl}-4-chlorobenzamide;

4-chloro-N-[ (5-{ [4-(2-phenylethyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[ (5-{ [4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

2-(5-{ [4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)-N-(4-chlorophenyl)acetamide;

2-{1-[ (5-{ [(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-2H-1,2,3-benzotriazole-5-carboxylic acid;

4-chloro-N-[ (5-{ [4-(5-chloro-1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

methyl 1-{1-[ (5-{ [(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-1H-1,2,3-benzotriazole-5-carboxylate;

methyl 1-{1-[ (5-{ [(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-1H-1,2,3-benzotriazole-6-carboxylate;

Appln. No. 10/070,954  
Amd. dated June 18, 2007  
Reply to Office Action of January 18, 2007  
Advisory Actions of May 2 and May 30, 2007

methyl 2-{1-[ (5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-2H-1,2,3-benzotriazole-5-carboxylate;

4-chloro-N-[(5-{[4-(6-chloro-1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-{[5-({4-[5-(trifluoromethyl)-1H-1,2,3-benzotriazol-1-yl]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

N-[(5-{[4-(7-aza-1H-benzimidazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

1-{1-[ (5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-1H-1,2,3-benzotriazole-5-carboxylic acid;

1-{1-[ (5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-1H-1,2,3-benzotriazole-6-carboxylic acid;

N-[(5-{[4-(2-amino-9H-purin-9-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-[(5-{[4-(9H-purin-9-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[(5-{[4-(6-amino-9H-purin-9-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-((5-[(4-{6-nitro-1H-benzimidazol-1-yl)piperidin-1-yl}sulfonyl]thien-2-yl)methyl)benzamide;

Appn. No. 10/070,954  
Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2 and May 30, 2007

4-chloro-N-({5-[ (4-{5-nitro-1H-benzimidazol-1-yl}piperidin-1-yl)sulfonyl]thien-2-yl)methyl)benzamide;

4-chloro-N-[ (5-[4-(2H-1,2,3-triazol-2-yl)piperidin-1-yl]sulfonyl)thien-2-yl)methyl]benzamide;

N-[ (5-[4-(1H-benzimidazol-1-yl)piperidin-1-yl]sulfonyl)thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-{ [5-({4-[3-propylanilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

4-chloro-N-{ [5-({4-[3-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

4-chloro-N-{ [5-({4-[3-(dimethylamino)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

methyl 3-((1-[(5-[ (4-chlorobenzoyl)amino]-methyl)thien-2-yl)sulfonyl]piperidin-4-yl)amino)-benzoate;

4-chloro-N-{ [5-({4-[3-(methylsulfanyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

4-chloro-N-({5-[ (4-{3-nitroanilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

4-chloro-N-[ (5-[4-(2-methoxyanilino)piperidin-1-yl]sulfonyl)thien-2-yl)methyl]benzamide;

Appn. No. 10/070,954  
Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2 and May 30, 2007

3-((1-[(5-[(4-chlorobenzoyl)amino]methyl)thien-2-yl)sulfonyl]piperidin-4-yl)amino)benzamide;

4-chloro-N-[(5-[(4-[2-(trifluoromethyl)anilino]piperidin-1-yl)sulfonyl)thien-2-yl)methyl]benzamide;

4-chloro-N-((5-[(4-(2-nitro-4-[(trifluoromethyl)sulfonyl]anilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl)benzamide;

4-chloro-N-[(5-[(4-(4-chloroanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-[(4-[4-(trifluoromethyl)anilino]piperidin-1-yl)sulfonyl)thien-2-yl)methyl]benzamide;

4-chloro-N-((5-[(4-(trifluoromethyl)sulfonyl]anilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl)benzamide;

4-chloro-N-((5-[(4-(2-nitroanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl)benzamide;

N-[(5-[(4-[4-(aminocarbonyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-[(5-[(4-[4-(1,3-dithiolan-2-yl)anilino]piperidin-1-yl)sulfonyl)thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954

Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2 and May 30, 2007

N-[(5-[[4-(3-chloroanilino)piperidin-1-yl]sulfonyl]thien-2-yl)methyl]-3-nitrobenzamide;

4-chloro-N-[(5-[[4-(3-chloroanilino)piperidin-1-yl]sulfonyl]thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-[[4-(3-methoxyanilino)piperidin-1-yl]sulfonyl]thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-[[4-[3-(methylsulfonyl)anilino]piperidin-1-yl]sulfonyl]thien-2-yl)methyl]benzamide;

N-((5-[(4-[3-[amino(imino)methyl]anilino)piperidin-1-yl]sulfonyl]thien-2-yl)methyl)-4-chlorobenzamide;

4-chloro-N-((5-[(4-[3-[(2-hydroxyethyl)sulfonyl]anilino)piperidin-1-yl]sulfonyl]thien-2-yl)methyl)benzamide;

N-[(5-[[4-(2-aminoanilino)piperidin-1-yl]sulfonyl]thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-[(5-[[4-(2-hydroxyanilino)piperidin-1-yl]sulfonyl]thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-[[4-(4-hydroxyanilino)piperidin-1-yl]sulfonyl]thien-2-yl)methyl]benzamide;

4-chloro-N-((5-[(4-[3-[(trifluoromethyl)sulfanyl]anilino)piperidin-1-yl]sulfonyl]thien-2-yl)methyl)benzamide;

Appln. No. 10/070,954  
Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007  
Advisory Actions of May 2 and May 30, 2007

4-chloro-N-[ (5-{ [4-(3-toluidino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[ (5-{ [4-{ [3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[ {5-{ [4-[3-(1,3-oxazol-5-yl)anilino]piperidin-1-yl]sulfonyl}thien-2-yl}methyl]benzamide;

N-[ (5-{ [4-(3-tert-butyylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-[ (5-{ [4-(2-propylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[ {5-{ [4-[ (2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]piperidin-1-yl]sulfonyl}thien-2-yl}methyl]benzamide;

4-chloro-N-[ (5-{ [4-(2,3-dihydro-1H-inden-5-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[ (5-{ [4-(4-propylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[ (5-{ [4-( {3-nitropyridin-2-yl}amino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[ {5-{ [4-[ (3-aminopyridin-2-yl)amino]piperidin-1-yl]sulfonyl}thien-2-yl}methyl]-4-chlorobenzamide;

Appn. No. 10/070,954  
Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2 and May 30, 2007

N-[(5-{[4-([1,1'-biphenyl]-3-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

N-[(5-{[4-(3-benzylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-[(5-{[4-(pyrimidin-2-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-[4-(morpholin-4-ylsulfonyl)anilino]piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(3-cyclohexyl-4-hydroxyanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[(5-{[4-(3-{(butylamino)sulfonyl}anilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-[(5-{[4-(3-ethylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(5,6,7,8-tetrahydronaphthalen-1-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[(5-{[4-[3-(aminosulfonyl)anilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

Appn. No. 10/070,954  
Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007  
Advisory Actions of May 2 and May 30, 2007

4-chloro-N-[ (5-{ [4-(quinolin-5-ylamino)piperidin-1-  
yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[ (5-{ [4-(quinolin-8-ylamino)piperidin-1-  
yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-Chloro-N-[ (5-{ [4-(3-propylphenoxy)piperidin-1-  
yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-nitro-N-({5-[ (4-{3-  
[(trifluoromethyl)sulfonyl]anilino}piperidin-1-  
yl)sulfonyl}thien-2-yl)methyl]benzamide;

N-[ (5-{ [4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-  
yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

4-nitro-N-({5-[ (4-{3-  
[(trifluoromethyl)sulfonyl]anilino}piperidin-1-  
yl)sulfonyl}thien-2-yl)methyl]benzamide;

N-[ (5-{ [4-(2,4-difluorobenzoyl)piperidin-1-  
yl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide;

N-[ (5-{ [4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-  
yl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide;

N-[ (5-{ [4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-  
yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

4-nitro-N-({5-[ (4-{3-  
[(trifluoromethyl)sulfonyl]anilino}piperidin-1-  
yl)sulfonyl}thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954

Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2 and May 30, 2007

N-[ (5-{[4-(2,4-difluorobenzoyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide;

N-[ (5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide;

3-nitro-N-[ (5-{[4-(3-methoxyanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

3-nitro-N-[5-({4-[3-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl]benzamide;

N-[ [5-({4-[3-(dimethylamino)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl]-3-nitrobenzamide;

3-nitro-N-[5-({4-[3-(methylsulfonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl]benzamide;

3-nitro-N-[5-({4-[3-(methylsulfanyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl]benzamide;

N-[ [5-({4-[3-(aminosulfonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl]-3-nitrobenzamide;

methyl 3-{[1-(({5-[(3-nitrobenzoyl)amino]methyl}-thien-2-yl)sulfonyl)-piperidin-4-yl]amino}benzoate;

N-[ [5-({4-[3-(aminocarbonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl]-3-nitrobenzamide;

Appln. No. 10/070,954  
Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007  
Advisory Actions of May 2 and May 30, 2007

3-nitro-N-((5-[(4-(3-nitroanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl)benzamide;

3-nitro-N-((5-[(4-(2-methoxyanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl)benzamide;

3-nitro-N-((5-((4-[2-(trifluoromethyl)anilino)piperidin-1-yl)sulfonyl)thien-2-yl)methyl)benzamide;

3-nitro-N-((5-[(4-(2-nitroanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl)benzamide;

N-((5-[(4-(4-chloroanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl)-3-nitrobenzamide;

3-nitro-N-((5-((4-[2-(trifluoromethyl)anilino)piperidin-1-yl)sulfonyl)thien-2-yl)methyl)benzamide;

3-nitro-N-((5-((4-[2-(trifluoromethyl)sulfonyl]anilino)piperidin-1-yl)sulfonyl)thien-2-yl)methyl)benzamide;

N-((5-((4-[2-(aminocarbonyl)anilino)piperidin-1-yl)sulfonyl)thien-2-yl)methyl)-3-nitrobenzamide;

N-((5-((4-(3-propylanilino)piperidin-1-yl)sulfonyl)thien-2-yl)methyl)-3-nitrobenzamide;

N-((5-((4-(3-chloroanilino)piperidin-1-yl)sulfonyl)thien-2-yl)methyl)-4-nitrobenzamide;

Appn. No. 10/070,954  
Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2 and May 30, 2007

4-nitro-N-[ (5-{ [4-(3-methoxyanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-nitro-N-[ 5-{ [4-[3-(trifluoromethyl)anilino]piperidin-1-yl]sulfonyl}thien-2-yl]methyl]benzamide;

N-[ 5-{ [4-[3-(dimethylamino)anilino]piperidin-1-yl]sulfonyl}thien-2-yl]methyl]-4-nitrobenzamide;

4-nitro-N-[ (5-{ [4-(3-propylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-nitro-N-[ 5-{ [4-[3-(methylsulfonyl)anilino]piperidin-1-yl]sulfonyl}thien-2-yl]methyl]benzamide;

4-nitro-N-[ 5-{ [4-[3-(methylsulfanyl)anilino]piperidin-1-yl]sulfonyl}thien-2-yl]methyl]benzamide;

N-[ 5-{ [4-[3-(aminosulfonyl)anilino]piperidin-1-yl]sulfonyl}thien-2-yl]methyl]-4-nitrobenzamide;

methyl 3-{[1-({5-[({4-nitrobenzoyl})amino)methyl]-thien-2-yl}sulfonyl)piperidin-4-yl]amino}benzoate;

3-{[1-({5-[({4-nitrobenzoyl})amino)methyl]}thien-2-yl)sulfonyl)piperidin-4-yl]amino}benzamide;

4-nitro-N-[ (5-[ (4-{3-nitroanilino}piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954  
Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2 and May 30, 2007

4-nitro-N-[ (5-{ [4-(2-methoxyanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-nitro-N-[5-{4-[2-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl]thien-2-yl)methyl]benzamide;

4-nitro-N-[ (5-[ (4-(2-nitroanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide;

N-[ (5-{ [4-(4-chloroanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide;

4-nitro-N-[5-{4-[4-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl]thien-2-yl)methyl]benzamide;

4-nitro-N-[ (5-[ (4-{4-[ (trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide;

N-[5-{4-[4-(aminocarbonyl)anilino]piperidin-1-yl}sulfonyl]thien-2-yl)methyl]-4-nitrobenzamide;

N-[5-{4-[4-(1,3-dithiolan-2-yl)anilino]piperidin-1-yl}sulfonyl]thien-2-yl)methyl]-4-nitrobenzamide;

N-[5-{(4-{3-[amino(imino)methyl]anilino}piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

N-[5-{(4-{3-[ (2-hydroxyethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

Appln. No. 10/070,954

Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2 and May 30, 2007

N-({5-[{4-anilinopiperidin-1-yl}sulfonyl]thien-2-yl}methyl)-3-nitrobenzamide;

N-({5-[{4-{3-[{2-hydroxyethyl}sulfonyl]anilino}piperidin-1-yl}sulfonyl]thien-2-yl}methyl)-4-nitrobenzamide;

N-({5-[{4-anilinopiperidin-1-yl}sulfonyl]thien-2-yl}methyl)-4-nitrobenzamide;

N-({5-[{4-{3-[amino(imino)methyl]anilino}piperidin-1-yl}sulfonyl]thien-2-yl}methyl)-4-nitrobenzamide;

3-nitro-N-({5-[{4-{3-[{trifluoromethyl}sulfanyl]anilino}piperidin-1-yl}sulfonyl]thien-2-yl}methyl)benzamide;

4-nitro-N-({5-[{4-{3-[{trifluoromethyl}sulfanyl]anilino}piperidin-1-yl}sulfonyl]thien-2-yl}methyl)benzamide;

3-nitro-N-[(5-[{4-{3-nitropyridin-2-yl}amino}piperidin-1-yl}sulfonyl]thien-2-yl)methyl]benzamide;

N-[(5-[{4-[{2,2-dioxido-1,3-dihydro-2-benzothien-5-yl}amino}piperidin-1-yl}sulfonyl]thien-2-yl)methyl]-3-nitrobenzamide;

N-[(5-[{4-(2,3-dihydro-1H-inden-5-ylamino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl]-3-nitrobenzamide;

3-nitro-N-[(5-[{4-(2-propylanilino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954

Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2 and May 30, 2007

3-nitro-N-[ (5-{ [4-(4-propylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[ (5-{ [4-(3-tert-butyylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

3-nitro-N-[ 5-{ [4-[3-(1,3-oxazol-5-yl)anilino)piperidin-1-yl]sulfonyl}thien-2-yl]methyl]benzamide;

3-nitro-N-[ (5-{ [4-(2-phenylethyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[ (5-[ (4-{ [3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino)piperidin-1-yl]sulfonyl]thien-2-yl)methyl]-3-nitrobenzamide;

N-[ (5-{ [4-([1,1'-biphenyl]-3-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

N-[ (5-{ [4-(3-benzylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

3-nitro-N-[ 5-{ [4-[3-(morpholin-4-ylsulfonyl)anilino)piperidin-1-yl]sulfonyl}thien-2-yl]methyl]benzamide;

3-nitro-N-[ (5-{ [4-(3-propylphenoxy)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-nitro-N-[ (5-{ [4-(pyrimidin-2-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2 and May 30, 2007

N-{[5-({4-[{3-aminopyridin-2-yl}amino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}-4-nitrobenzamide;

4-nitro-N-{[5-{[4-({3-nitropyridin-2-yl}amino)piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

N-{[(5-{[4-(2,3-dihydro-1H-inden-5-ylamino)piperidin-1-yl}sulfonyl)thien-2-yl]methyl}-4-nitrobenzamide;

4-nitro-N-{[5-{[4-(2-propylanilino)piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

4-nitro-N-{[5-{[4-(4-propylanilino)piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

N-{[(5-{[4-(3-tert-butyylanilino)piperidin-1-yl}sulfonyl)thien-2-yl]methyl}-4-nitrobenzamide;

4-nitro-N-{[5-{[4-[3-(1,3-oxazol-5-yl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

4-nitro-N-{[5-{[4-(2-phenylethyl)piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

N-{[(5-{[4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}-4-nitrobenzamide;

N-{[(5-{[4-([1,1'-biphenyl]-3-ylamino)piperidin-1-yl}sulfonyl)thien-2-yl]methyl}-4-nitrobenzamide;

N-{[(5-{[4-(3-benzylanilino)piperidin-1-yl}sulfonyl)thien-2-yl]methyl}-4-nitrobenzamide;

Appn. No. 10/070,954

Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2 and May 30, 2007

4-nitro-N-{[5-{[4-[3-(morpholin-4-ylsulfonyl)anilino]piperidin-1-yl}sulfonyl]thien-2-yl}methyl}benzamide;

N-[(5-{[4-(2-aminoanilino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl]-3-nitrobenzamide;

3-nitro-N-[(5-{[4-(pyrimidin-2-ylamino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl]benzamide;

N-{[5-{[4-[(3-aminopyridin-2-yl)amino]piperidin-1-yl}sulfonyl]thien-2-yl)methyl}-3-nitrobenzamide;

N-({5-[(4-{2-nitro-4-[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}-3-methoxybenzamide;

3-nitro-N-({5-[(4-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

N-[(5-{[4-(3-cyclohexyl-4-hydroxyanilino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl]-3-nitrobenzamide;

N-({5-[(4-{3-[(butylamino)sulfonyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}-3-nitrobenzamide;

N-[(5-{[4-(3-ethylanilino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl]-3-nitrobenzamide;

3-nitro-N-[(5-{[4-(5,6,7,8-tetrahydronaphthalen-1-ylamino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954  
Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007  
Advisory Actions of May 2 and May 30, 2007

4-nitro-N-[ (5-{ [4-(3-propylphenoxy)piperidin-1-  
yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[ (5-{ [4-(2,4-difluorobenzoyl)piperidin-1-  
yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

N-[ (5-{ [4-(2,4-difluorobenzoyl)piperidin-1-  
yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

2-Hydroxy-N-[ {5-[ (4-{3-  
[(trifluoromethyl)sulfonyl]anilino)piperidin-1-  
yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[ (5-{ [4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-  
yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

N-[ (5-{ [4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-  
yl]sulfonyl}thien-2-yl)methyl]-2-hydroxybenzamide;

N-[ {5-[ {4-[ (1,3-dithiolan-2-yl)anilino]}piperidin-  
1-yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

3-methoxy-N-[ (5-{ [4-(3-methoxyanilino)piperidin-1-  
yl]sulfonyl}thien-2-yl)methyl]benzamide;

3-methoxy-N-[ {5-[ {4-[ (3-  
(trifluoromethyl)anilino)piperidin-1-yl}sulfonyl}thien-2-  
yl)methyl]benzamide;

N-[ {5-[ {4-[ (3-dimethylamino)anilino]}piperidin-1-  
yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

3-methoxy-N-[ (5-{ [4-(3-propylanilino)piperidin-1-  
yl]sulfonyl}thien-2-yl)methyl]benzamide;

Appn. No. 10/070,954  
Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007  
Advisory Actions of May 2 and May 30, 2007

3-methoxy-N-[5-((4-[3-(methylsulfonyl)anilino]piperidin-1-yl)sulfonyl)thien-2-yl]methyl}benzamide;

3-methoxy-N-[5-((4-[3-(methylsulfanyl)anilino]piperidin-1-yl)sulfonyl)thien-2-yl]methyl}benzamide;

N-[5-((4-[3-(aminosulfonyl)anilino]piperidin-1-yl)sulfonyl)thien-2-yl]methyl}-3-methoxybenzamide;

methyl 3-((1-[(5-{[(3-methoxybenzoyl)amino]-methyl}thien-2-yl)sulfonyl]piperidin-4-yl)amino)-benzoate;

N-[5-((4-[3-(aminocarbonyl)anilino]piperidin-1-yl)sulfonyl)thien-2-yl]methyl}-3-methoxybenzamide;

3-methoxy-N-[(5-[(4-(2-methoxyanilino)piperidin-1-yl)sulfonyl)thien-2-yl)methyl]benzamide;

N-[(5-[(4-{3-nitroanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;

3-methoxy-N-[5-((4-[2-(trifluoromethyl)anilino]piperidin-1-yl)sulfonyl)thien-2-yl]methyl}benzamide;

N-[(5-[(4-{2-nitroanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;

N-[5-((4-[4-(aminocarbonyl)anilino]piperidin-1-yl)sulfonyl)thien-2-yl]methyl}-3-methoxybenzamide;

Appln. No. 10/070,954  
Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007  
Advisory Actions of May 2 and May 30, 2007

N-[5-[(4-[4-(1,3-dithiolan-2-yl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;

N-[(5-[(4-(3-chloroanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;

N-[(5-[(4-(4-chloroanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;

3-methoxy-N-[(5-[(4-(trifluoromethyl)sulfonyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl)benzamide;

N-[(5-[(4-(3-[amino(imino)methyl]anilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;

N-[(5-[(4-(3-[hydroxyethyl)sulfonyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;

3-methoxy-N-[(5-[(4-(trifluoromethyl)sulfonyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl)benzamide;

N-[(5-[(4-anilinopiperidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;

3-methoxy-N-[(5-[(4-(trifluoromethyl)sulfanyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl)benzamide;

N-[(5-[(4-(4-hydroxyanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;

Appln. No. 10/070,954  
Amd. dated June 18, 2007  
Reply to Office Action of January 18, 2007  
Advisory Actions of May 2 and May 30, 2007

3-nitro-N-[(5-[(4-{3-  
[(trifluoromethyl)sulfanyl]anilino}piperidin-1-  
yl)sulfonyl]thien-2-yl)methyl]benzamide;  
4-nitro-N-[(5-[(4-{3-  
[(trifluoromethyl)sulfanyl]anilino}piperidin-1-  
yl)sulfonyl]thien-2-yl)methyl]benzamide;  
N-[(5-[(4-(2-hydroxyanilino)piperidin-1-  
yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;  
3-methoxy-N-[(5-[(4-(pyrimidin-2-ylamino)piperidin-1-  
yl)sulfonyl]thien-2-yl)methyl]benzamide;  
N-[(5-[(4-(3-aminopyridin-2-yl)amino)piperidin-1-  
yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;  
N-[(5-[(4-(3-nitropyridin-2-yl)amino)piperidin-1-  
yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;  
N-[(5-[(4-[(2,2-dioxido-1,3-dihydro-2-benzothien-5-  
yl)amino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-  
methoxybenzamide;  
N-[(5-[(4-(2,3-dihydro-1H-inden-5-ylamino)piperidin-1-  
yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;  
3-methoxy-N-[(5-[(4-(2-propylanilino)piperidin-1-  
yl)sulfonyl]thien-2-yl)methyl]benzamide;  
3-methoxy-N-[(5-[(4-(4-propylanilino)piperidin-1-  
yl)sulfonyl]thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954  
Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2 and May 30, 2007

N-[ (5-{ [4-(3-tert-butylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

N-({5-[ (4-{ [3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}piperidin-1-yl)sulfonyl}thien-2-yl)methyl)-3-methoxybenzamide;

3-methoxy-N-[5-({4-[3-(1,3-oxazol-5-yl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

N-[ (5-{ [4-([1,1'-biphenyl]-3-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

3-methoxy-N-[ (5-{ [4-(3-propylphenoxy)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

3-methoxy-N-[5-({4-[3-(morpholin-4-ylsulfonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

3-methoxy-N-[ (5-{ [4-(2-phenylethyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[ (5-{ [4-(3-benzylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

3-methoxy-N-({5-[ (4-{ [4-(trifluoromethyl)pyrimidin-2-yl]amino}piperidin-1-yl)sulfonyl}thien-2-yl)methyl}benzamide;

N-[ (5-{ [4-(3-cyclohexyl-4-hydroxyanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2 and May 30, 2007

N- [{ 5- [ (4-{ 3-

[ (butylamino)sulfonyl]anilino}piperidin-1-yl)sulfonyl]thien-2-  
yl}methyl)-3-methoxybenzamide;

N- [ (5-{ [4-(3-ethylanilino)piperidin-1-  
yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

3-methoxy-N- [ (5-{ [4-(5,6,7,8-tetrahydronaphthalen-1-  
ylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide;

N- [ (5-{ [4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-  
yl]sulfonyl}thien-2-yl)methyl]-5-nitro-1H-pyrazole-3-  
carboxamide;

N- [ (5-{ [4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-  
yl]sulfonyl}thien-2-yl)methyl]-2-oxo-1,2-dihdropyridine-3-  
carboxamide;

N- [ (5-{ [4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-  
yl]sulfonyl}thien-2-yl)methyl]-2-thioxo-1,2-dihdropyridine-3-  
carboxamide;

N- [ (5-{ [4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-  
yl]sulfonyl}thien-2-yl)methyl]-3,4-dihydroxybenzamide;

N- [ (5-{ [4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-  
yl]sulfonyl}thien-2-yl)methyl]pyridine-2-carboxamide;

N- [ (5-{ [4-(hexyloxy)piperidin-1-yl)sulfonyl}thien-2-  
yl)methyl]-3-methoxybenzamide;

N- ({ 5- [ (4-heptanoylpiperidin-1-yl)sulfonyl]thien-2-  
yl)methyl)-3-methoxybenzamide;

Appn. No. 10/070,954

Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2 and May 30, 2007

4-chloro-N-[ (5-{ [4-(3-propylanilino)piperidin-1-yl]sulfonyl}-2-furyl)methyl]benzamide;

4-chloro-N-[ (5-{ [4-(3-chloroanilino)piperidin-1-yl]sulfonyl}-2-furyl)methyl]benzamide;

4-chloro-N-[ (5-{ [4-(3-methoxyanilino)piperidin-1-yl]sulfonyl}-2-furyl)methyl]benzamide;

4-chloro-N-[ 5-{ {4-[3-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl}-2-furyl]methyl]benzamide;

4-chloro-N-[ 5-{ {4-[3-(dimethylamino)anilino]piperidin-1-yl}sulfonyl}-2-furyl]methyl]benzamide;

4-chloro-N-[ 5-{ {4-[3-(methylsulfonyl)anilino]piperidin-1-yl}sulfonyl}-2-furyl]methyl]benzamide;

4-chloro-N-[ 5-{ {4-[3-(methylsulfanyl)anilino]piperidin-1-yl}sulfonyl}-2-furyl]methyl]benzamide;

N-[ 5-{ {4-[3-(aminosulfonyl)anilino]piperidin-1-yl}sulfonyl}-2-furyl]methyl]-4-chlorobenzamide;

methyl 3-{ {1-[ (5-{ [(4-chlorobenzoyl)amino]methyl}-2-furyl)sulfonyl]piperidin-4-yl}amino}benzoate;

3-{ {1-[ (5-{ [(4-chlorobenzoyl)amino]methyl}-2-furyl)sulfonyl]piperidin-4-yl}amino}benzamide;

Appln. No. 10/070,954

Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2 and May 30, 2007

4-chloro-N-({5-[ (4-{3-nitroanilino}piperidin-1-yl)sulfonyl]-2-furyl}methyl)benzamide;

4-chloro-N-[ (5-{ [4-(2-methoxyanilino)piperidin-1-yl]sulfonyl}-2-furyl)methyl]benzamide;

4-chloro-N-{ [5-( {4-[2-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl)-2-furyl]methyl}benzamide;

4-chloro-N-({5-[ (4-{2-nitroanilino}piperidin-1-yl)sulfonyl]-2-furyl}methyl)benzamide;

4-chloro-N-[ (5-{ [4-(4-chloroanilino)piperidin-1-yl]sulfonyl}-2-furyl)methyl]benzamide;

4-chloro-N-{ [5-( {4-[4-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl)-2-furyl]methyl}benzamide;

4-chloro-N-{ [5-[ (4-{4-[ (trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]-2-furyl]methyl}benzamide;

N-{ [5-( {4-[4-(aminocarbonyl)anilino]piperidin-1-yl}sulfonyl)-2-furyl]methyl}-4-chlorobenzamide;

4-chloro-N-{ [5-( {4-[4-(1,3-dithiolan-2-yl)anilino]piperidin-1-yl}sulfonyl)-2-furyl]methyl}benzamide;

N-{ [5-( {4-{3-[amino(imino)methyl]anilino}piperidin-1-yl}sulfonyl)-2-furyl]methyl}-4-chlorobenzamide;

Appln. No. 10/070,954  
Amd. dated June 18, 2007  
Reply to Office Action of January 18, 2007  
Advisory Actions of May 2 and May 30, 2007

4-chloro-N-((5-[ (4-{3-[ (trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]-2-furyl)methyl)benzamide;

N-((5-[ (4-anilinopiperidin-1-yl)sulfonyl]-2-furyl)methyl)-4-chlorobenzamide; and

4-nitro-N-((5-[ (4-{3-[ (trifluoromethyl)sulfanyl]anilino}piperidin-1-yl)sulfonyl]-2-furyl)methyl)benzamide.

12. (Previously Presented) A sulfonamide compound according to claim 11, which is selected from the group consisting of:

4-chloro-N-[(5-{[4-(2,4-difluorobenzoyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-((5-[ (4-anilinopiperidin-1-yl)sulfonyl]thien-2-yl)methyl)-4-chlorobenzamide;

N-[(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

N-[(5-{[4-(1H-benzimidazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-[(5-{[4-[3-propylanilino]piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(4-chloroanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954

Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2 and May 30, 2007

4-chloro-N-((5-[ (4-{3-[ (2-hydroxyethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl)benzamide;

N-[(5-[(4-[3-(aminosulfonyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-4-chlorobenzamide;

4-nitro-N-[(5-[(4-(3-methoxyanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide;

methyl 3-[(1-((5-[(4-nitrobenzoyl)amino]methyl)thien-2-yl)sulfonyl)piperidin-4-yl]amino}benzoate;

N-[(5-[(4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-2-hydroxybenzamide; and


N-((5-[(4-(2-nitroanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl)-3-methoxybenzamide.

Claims 13-19. (Cancelled)

20. (Previously Presented) A pharmaceutical composition containing at least one sulfonamide compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.


21. (Previously Presented) Process for the preparation of a sulfonamide compound according to claim 1, comprising reacting a sulfonyl chloride V

Appln. No. 10/070,954  
Amd. dated June 18, 2007  
Reply to Office Action of January 18, 2007  
Advisory Actions of May 2 and May 30, 2007



V

with an amine VIII



VIII


whereby  $(\text{R}^6)_n$ ,  $\text{L}^1$  and  $\text{L}^2$  are as defined in claim 1.

22. (Previously Presented) A process according to  
claim 21, wherein said sulfonyl chloride V is obtained by  
a) coupling an amine of formula II:




II

with an acyl chloride of formula III:



III

to provide an amide of formula IV:




IV

Appl. No. 10/070,954  
Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2 and May 30, 2007

b) sulfonating the amide of formula IV to provide a sulfonyl chloride V



V.

Claims 23-26. (Cancelled)

27. (Previously Presented) The sulfonamide compound according to claim 1 wherein n is an integer of from 1 to 3.

28. (Previously Presented) The sulfonamide compound according to claim 27 wherein n is 1.

29. (Previously Presented) The composition according to claim 2 wherein n is an integer of from 1 to 3.

30. (Previously Presented) The composition according to claim 29 wherein n is 1.

31. (Previously Presented) The composition according to claim 3 wherein n is 1 or 2.

Claims 32-34. (Cancelled)

35. (Previously Presented) The sulfonamide compound according to claim 5 wherein the C<sub>1</sub>-C<sub>6</sub> alkyl group is trihalomethyl.

Appln. No. 10/070,954  
Amd. dated June 18, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2 and May 30, 2007

36. (Previously Presented) The sulfonamide compound according to claim 10 wherein L<sup>1</sup> is a triazole ring which is fused with an unsubstituted or substituted aryl ring.

Claims 37-41. (Cancelled)